ALGN or WST: Which Is the Better Value Stock Right Now?

Thursday, Mar 19, 2026 12:42 pm ET2min read
ALGN--
WST--
Aime RobotAime Summary

- Align TechnologyALGN-- (ALGN) and West Pharmaceutical ServicesWST-- (WST) are compared as potential undervalued medical-dental stocks.

- Both hold a Zacks Rank of #2 (Buy), but ALGNALGN-- earns a stronger Value grade (B vs. D) via better valuation metrics.

- ALGN shows lower forward P/E (15.38 vs. 30.42) and P/B (3.06 vs. 5.42), with more favorable PEG ratios (1.53 vs. 2.56).

- Analysts conclude ALGN offers superior value despite both companies' improving earnings outlooks.

Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align TechnologyALGN-- (ALGN) and West Pharmaceutical ServicesWST-- (WST). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Right now, both Align Technology and West Pharmaceutical Services are sporting a Zacks Rank of #2 (Buy). Investors should feel comfortable knowing that both of these stocks have an improving earnings outlook since the Zacks Rank favors companies that have witnessed positive analyst estimate revisions. But this is just one factor that value investors are interested in.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value.

ALGN currently has a forward P/E ratio of 15.38, while WSTWST-- has a forward P/E of 30.42. We also note that ALGNALGN-- has a PEG ratio of 1.53. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. WST currently has a PEG ratio of 2.56.

Another notable valuation metric for ALGN is its P/B ratio of 3.06. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, WST has a P/B of 5.42.

Based on these metrics and many more, ALGN holds a Value grade of B, while WST has a Value grade of D.

Both ALGN and WST are impressive stocks with solid earnings outlooks, but based on these valuation figures, we feel that ALGN is the superior value option right now.

Quantum Computing Stocks Set To Soar

Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.

Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.

Access the Report Free Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report



Align Technology, Inc. (ALGN): Free Stock Analysis Report

West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet